Table 5.
Current malaria vaccines with delivery systems in clinical trials.
| Vaccine candidate | Clinical trial registration number | Stage | Delivery system | Antigen(s) | Species and strain of malaria parasite | Adjuvants used |
|---|---|---|---|---|---|---|
| Pre-erythrocytic projects | ||||||
| RTS,S/AS01E | NCT00866619 | Phase III | VLP | Pf CSP (207–395)& HBsAg | P. falciparum | AS01E |
| RTS,S-AS01 fractional dose regimes | NCT02992119 | Phase II | VLP | Pf CSP (207–395)& HBsAg | P. falciparum | AS01B /AS01E |
| ChAd63/MVA ME-TRAP | NCT01635647 (VAC050) | Phase I/IIb | ChAd63, MVA | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | P. falciparum | |
| ChAd63/MVA ME-TRAP +Matrix M™ | NCT01669512 (VAC048) | Phase I | ChAd63, MVA | TRAP + ME epitopes (CS, LSA1, LSA3, STARP, EXP1, pb9) | P. falciparum | Matrix M™ |
| CSVAC | NCT01450280 | Phase I | ChAd63, MVA | CS | P. falciparum | |
| R21/Matrix-M1 | NCT04704830 | Phase III | VLP | CSP less- HBsA | P. falciparum | Matrix-M1 |
| adjuv R21 (RTS,S-biosimilar) with ME-TRAP combined | NCT02905019 | Phase I/IIa | ChAd63, MVA | CSP less- HBsA + MeTRAPg | P. falciparum | Matrix-M1 |
| Blood stage projects | ||||||
| ChAd63 RH5 +/- MVA RH5 | NCT02181088 | Phase Ia | ChAd63, MVA | RH5 | P. falciparum | |
| ChAd63/MVA PvDBP | NCT01816113 | Phase Ia | ChAd63, MVA | PvDBP_RII | P. vivax | |
| Sexual stage projects | ||||||
| Pfs25 VLP | NCT02013687 | Phase I/IIa | VLP | Pfs25 | P. falciparum | Alhydrogel |
| ChAd63 Pfs25-IMX313/MVA Pfs25-IMX313 | NCT02532049 | Phase Ia | ChAd63, MVA | Pfs25 | P. falciparum | |